Abstract
The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an agent capable of exerting a cytotoxic effect on the tum or cell. The target recognition segment derived form the natural killer recepto r NKp30 has been found to be particularly effective in vivo.
| Original language | English |
|---|---|
| Patent number | CA2509400 |
| IPC | C12N 15/ 62 A I |
| Priority date | 9/12/03 |
| State | Published - 24 Jun 2004 |